Pharmaceutical Technology

MAY 2, 2024

Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.

Sales 246

Sales Marketing Production 246

Bio Pharma Dive

MAY 2, 2024

First quarter sales of the in-demand obesity drug were down slightly compared to the fourth quarter last year, as the company tries to meet demand.

Sales 238

Sales Drugs 238

Pharmaceutical Technology

FEBRUARY 21, 2023

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast. Comirnaty is the first globally approved Covid-19 vaccine.

Sales 246

Sales Vaccination Vaccine Medicine 246

Bio Pharma Dive

JANUARY 31, 2024

The British drugmaker reported Arexvy sales of about $1.5 billion for 2023, higher than the range it had previously predicted for the year.

Sales 270

Sales Vaccination Vaccine 270

Bio Pharma Dive

NOVEMBER 2, 2023

The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.

Sales 287

Sales Drugs Production 287

Pharma Mirror

JUNE 23, 2023

In the fast-paced, highly competitive pharmaceutical industry, sales reps must adapt to new ways of engaging with customers and healthcare professionals (HCPs).

Sales 130

Sales Development Marketing 130

Bio Pharma Dive

OCTOBER 9, 2023

The purchase agreement with Chongqing Zhifei Biological Products is part of GSK’s plan to double sales of the shingles vaccine by 2026.

Sales 271

Sales Vaccination Vaccine Production 271

Bio Pharma Dive

APRIL 13, 2023

The Danish drugmaker nearly doubled the 2023 forecasts for Wegovy and Ozempic in the latest indicator of the sales potential of an emerging and competitive class of weight loss drugs.

Sales 319

Sales Drugs 319

Pharmaceutical Technology

MARCH 2, 2023

Merck has reported an increase in group net sales by 12.9% The growth in sales was driven by all regions and business sectors, particularly Life Science. in group sales in fiscal 2022. Additionally, due to the acquisition of Exelead, a biopharmaceutical contract development and manufacturing company, sales increased by 0.4%.

Sales 245

Sales Life Science Licensing Licensing 245

Bio Pharma Dive

NOVEMBER 3, 2022

The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product.

Sales 287

Sales Vaccination Vaccine Production 287

Bio Pharma Dive

NOVEMBER 9, 2022

While many companies are still unsure of the Inflation Reduction Act's effects, some have begun to warn investors about the likelihood of lower sales and reduced profitability.

Sales 311

Sales Development Drugs 311

Pharmaceutical Technology

JULY 31, 2023

Pharma sales have undergone a seismic transformation after Covid-19, with the adoption of artificial intelligence tools.

Sales 246

Sales 246

Pharmaceutical Technology

FEBRUARY 3, 2023

Merck (MSD outside North America) has reported a 2% increase in worldwide sales to $13.83bn in the fourth quarter (Q4) of 2022 from $13.52bn in the previous year’s quarter. The company’s pharmaceutical sales recorded a 1% rise to $12.18bn compared to $12.03bn in the prior-year quarter. in the same quarter last year.

Sales 246

Sales Engineer Vaccination Vaccine 246

Bio Pharma Dive

JANUARY 6, 2023

The gene therapy developer will receive $95 million from Bristol Myers Squibb, slightly less than it got in the recent sale of another priority review voucher.

Sales 298

Sales Gene Therapy Gene Development 298

Bio Pharma Dive

APRIL 23, 2024

Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise.

Sales 164

Sales Drugs 164

Bio Pharma Dive

JULY 27, 2022

A manufacturing issue for Breyanzi, meanwhile, impacted sales. Demand has increased faster than Bristol Myers can make Abecma, although the company said supply is improving.

Sales 280

Sales Production Manufacturing 280

Pharmaceutical Technology

MAY 14, 2024

Bayer announced a fall in Q1 sales and predicted future challenges in the Xarelto market in its Q1 update.

Sales 147

Sales Marketing 147

Bio Pharma Dive

AUGUST 3, 2023

Sales of the company’s COVID-19 vaccine plummeted 94% year over year. But executives believe newer products can help revenue rebound.

Sales 246

Sales Vaccination Vaccine Production 246

Pharmaceutical Technology

APRIL 16, 2024

Boehringer Ingelheim announced consistent growth across its human pharma sales and R&D investments in 2023.

Sales 130

Sales 130

Bio Pharma Dive

JANUARY 24, 2023

The drugmaker reported fourth quarter revenue that fell short of forecasts, but reiterated confidence in reaching a $60 billion pharmaceutical sales goal.

Sales 294

Sales Drugs 294

Pharmaceutical Technology

AUGUST 23, 2023

Physicians with experience with using AI in their practices were more open to sales representatives using AI to personalise messaging.

Sales 130

Sales 130

Pharmaceutical Technology

MAY 1, 2024

Last week, Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO, a vascular endothelial growth factor (VEGF) and angiopoietin-2 inhibitor for wet age-related macular degeneration (wAMD), diabetic macular oedema (DME), and macular oedema following retinal vein occlusion.

Sales 130

Sales 130

Bio Pharma Dive

DECEMBER 22, 2021

Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness.

Sales 339

Sales FDA Approval Doctors Doctor 339

Bio Pharma Dive

AUGUST 17, 2022

The federal government will begin the transition as early as this fall, clearing the way for drugmakers to control sales and distribution of their shots and therapeutics.

Sales 265

Sales Marketing Vaccination Vaccine 265

Bio Pharma Dive

AUGUST 23, 2022

The biotech successfully brought two medicines to market, but shares have lost most of their value amid sluggish sales.

Sales 273

Sales Medicine Drugs Marketing 273

Bio Pharma Dive

APRIL 18, 2023

Revenue topped analyst forecasts on strong market performance from the pharma’s multiple myeloma treatments, as well as the last quarter of significant COVID-19 vaccine sales.

Sales 213

Sales Vaccination Vaccine Drugs 213

Bio Pharma Dive

OCTOBER 28, 2021

But sales could climb even higher if it works as a preventive treatment too. Executives based their projections on contracts already in place for the drug, known as molnupiravir.

Sales 300

Sales Drugs 300

Bio Pharma Dive

OCTOBER 26, 2023

Company shares fell Thursday as the company adjusted its medium-term guidance for sales of new products like Reblozyl, Camzyos and Abecma.

Sales 164

Sales Drugs Production 164

Bio Pharma Dive

DECEMBER 5, 2023

The company expects its pharmaceutical division to deliver 20 new medicines through the end of the decade, including several it believes could earn peak annual sales of more than $5 billion.

Sales 156

Sales Medicine Drugs 156

Bio Pharma Dive

MAY 4, 2022

The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.

Sales 265

Sales Vaccination Vaccine 265

Bio Pharma Dive

JULY 21, 2021

billion in sales from its shot this year, despite concerns over protection against variants and significant manufacturing setbacks. The pharmaceutical company expects $2.5

Sales 288

Sales Vaccination Vaccine Manufacturing 288

pharmaphorum

JULY 11, 2024

SK Life Science Leverages Smart, Efficient Solutions Across its Engaged Industry-Leading Sales Team Mike.Hammerton Thu, 11/07/2024 - 08:00 Bookmark this

Life Science 103

Life Science Sales 103

Fierce Pharma

APRIL 2, 2024

After years of struggling with hurdles such as generic competition and significantly lower-than-expected sales of its top meds, Acorda Therapeutics is hanging up the gloves with a $185 million deal | Merz Therapeutics, in a "stalking horse bid," agreed to pick up Acorda's Parkinson's disease med Inbrija and multiple sclerosis drug (..)

Sales 114

Sales Drugs 114

Fierce Pharma

JUNE 17, 2024

Two back-to-back pivotal trial wins have rekindled hopes at GSK that once-failed multiple myeloma drug Blenrep could reach more than 3 billion pounds sterling in peak sales after all. |

Sales 116

Sales Marketing Trials Drugs 116

Bio Pharma Dive

FEBRUARY 5, 2021

Sales of the antiviral drug accounted for a quarter of the biotech's product revenue in the fourth quarter, disguising hits to its business elsewhere.

Sales 288

Sales Drugs Production 288

Bio Pharma Dive

FEBRUARY 2, 2023

Still, fourth quarter sales for Mounjaro were slightly below high Wall Street forecasts and didn’t offset falling revenue from Lilly’s COVID-19 antibodies.

Sales 156

Sales Antibody Drugs 156

Pharmaceutical Technology

APRIL 19, 2023

increase in sales to $24.75bn in the first quarter (Q1) of 2023, up from $23.4bn during the corresponding quarter of 2022. In the US, sales of J&J rose by 9.7% During this period, the company’s international sales grew by 1.8% from $12.01bn to $12.23bn, and worldwide sales rose by 5.6%. from $5.15bn in Q1 2022.

Sales 130

Sales Production Drugs 130